Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 1/2010

01-01-2010 | Drug and Profile Reports

Fesoterodine: a guide to its use in overactive bladder syndrome

Published in: Drugs & Therapy Perspectives | Issue 1/2010

Login to get access

Excerpt

Oral fesoterodine extended-release 4 or 8 mg once daily improved the symptoms associated with overactive bladder syndrome and health-related quality of life to a significantly greater extent than placebo in large, well designed clinical trials, and was generally well tolerated. Adapted from Drugs 2009; 69 (6): 731–-8.[1] …
Literature
1.
2.
3.
Toviaz™ (fesoterodine fumarate) extended-release tablets: US prescribing information. New York: Pfizer Inc., 2008 Nov
4.
Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. JUrol 2007; 178(6): 2488–94
5.
Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52(4): 1204–12PubMedCrossRef
6.
Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008; 71(5): 839–43PubMedCrossRef
7.
Chapple CR, Van Kerrebroeck PE, Jünemann K-P, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008; 102(9): 1128–32PubMedCrossRef
8.
Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008; 102(1): 56–61PubMedCrossRef
Metadata
Title
Fesoterodine: a guide to its use in overactive bladder syndrome
Publication date
01-01-2010
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 1/2010
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.2165/11202440-000000000-00000

Other articles of this Issue 1/2010

Drugs & Therapy Perspectives 1/2010 Go to the issue

Disease Management

Antidepressants are the main options for the long-term pharmacological treatment of generalized anxiety disorder

Drug Reactions and Interactions

Glitazones accelerate bone loss and increase the risk of fracture in patients with type 2 diabetes mellitus

Drug Reactions and Interactions

First reports of serious adverse drug reactions in recent weeks

Disease Management

Worldwide control of trachoma involves a strategy combining surgery, antibacterials, facial cleanliness and environmental improvements

Practical Issues and Updates

News from the 38th European Symposium on Clinical Pharmacy; 3–6 November 2009; Geneva

Drug and Profile Reports

Ferric carboxymaltose: a guide to its use in iron-deficiency anaemia